Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.

Abstract

OBJECTIVE The combination of an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II (Ang II) receptor antagonist (ARB) could provide a higher degree of blockade of the renin-angiotensin system(RAS) than either agent alone. The primary aim of this study was to look at the effect of three therapeutic regimens (titrated ACE inhibitor (ACE-I) versus titrated ARB versus the combination of an ACE-I and an ARB) on the attainment of adequate blood pressure (BP) control and antiproteinuric effect. Both ACE-I and ARB were titrated as monotherapy up to the maximal recommended dose. METHODS A pilot randomised, parallel group open-label study was conducted in 36 patients with primary renal disease, proteinuria above 1.5 g/day and BP >140/90 mmHg while on therapy with an ACE-I. Patients were randomly assigned to (1) benazepril, n=12; (2) valsartan, n=12; or (3) benazepril plus valsartan, n=12. Other antihypertensive therapies could also be added to attain goal BP (<140/90 mmHg). The primary endpoint was the change in proteinuria during six months of follow-up. RESULTS In the presence of similar BP decreases and stable creatinine clearance values, mean proteinuria decreases were 0.5+1.7, 1.2+2.0 and 2.5+1.8 g/day in groups 1, 2 and 3, respectively. When compared with baseline values, only the fall induced by the combination of ARB and ACE-I attained statistical significance (p<0.05). CONCLUSION The antiproteinuric capacity of monotherapy at recommended doses with either an ACE-I or an ARB is lower than that obtained with the combination of the two drugs.

Statistics

02040'05'06'07'08'09'10'11'12'13'14'15'16'17
Citations per Year

59 Citations

Semantic Scholar estimates that this publication has 59 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Segura2003CombinationIB, title={Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.}, author={Juli{\'a} Segura and Manuel Praga and Carlos E Campo and Jos{\'e} Louis Rodicio and Lu{\'i}s Miguel Ruilope}, journal={Journal of the renin-angiotensin-aldosterone system : JRAAS}, year={2003}, volume={4 1}, pages={43-7} }